



David Cook

Chief Scientific Officer


**An Introduction to
Blueberry Therapeutics**

Company Overview

- Founded November 2011 through private investment and grant funding
- An experienced, entrepreneurial core team with over 60 years experience in large and small pharma and Biotech
- Operates semi-virtually with a range of trusted experts and contract partners
- Exploiting a safe, easy to use nanotechnology drug delivery platform to develop new medicines in a range of disease indications
 - Infection and inflammation
 - Small and large molecule approaches
- Initial focus on the exploitation of a safe nanopolymer based drug delivery platform in over the counter (OTC) medicines
- Look for opportunities to collaborate with academic partners to drive forward our R&D projects and exploit our underlying technology platform
- Intellectual Property: 5 patents and 6 exclusive licenses to patented technology



Current Portfolio 2015




Exploiting our differentiating nanopolymer delivery platform in a range of over the counter healthcare products to marketing authorisation to rapidly generate revenue, benefit our shareholders and invest in long term projects



Drug delivery platform

Nanocin™: A safe nanopolymer-based drug delivery system

- A non-lipid polymer with with over 30 years safe clinical use in human health
- Nanocin™ rapidly assembles into nanoparticles – packaging the cargo drug for enhanced delivery




Blueberry is exploiting the unique properties of Nanocin™ to develop a range of topical treatments for infectious and inflammatory disease



Tackling Bacterial Antibiotic Resistance

Preclinical proof-of-concept studies




Restoration of antibiotic sensitivity in clinical isolates of MRSA by protein aptamers blocking the resistance mechanism

- A new approaches to the treatment of multidrug resistant infection
- A platform approach based on nanotech formulated peptide aptamers which target directly the mechanisms of bacterial resistance restoring sensitivity to standard antibiotics- RESISTANCE BREAKERS
- Used in combination with standard antibiotic treatments
 - Treat MRSA with penicillin!
 - Potential for a long-term sustained response to AMR



Blueberry collaborators



We are always keen to develop collaborations to help us drive forward our research and exploit this exciting new nanotechnology





Thank you

Contact: David Cook
david.cook@blueberrytherapeutics.com